In landmark study, drug-eluting stents prove more effective, equally as safe as bare-metal stents in heart attack patients

NEW YORK, NY – MAY 7, 2009 The Cardiovascular Research Foundation (CRF) announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published today in The New England Journal of Medicine. The study, HORIZONS-AMI (Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction), showed that in heart attack patients undergoing angioplasty, the use of paclitaxel-eluting stents reduces rates of target lesion revascularization (TLR) and binary angiographic restenosis when compared to the use of bare-metal stents after 1 year.

Welcome to the Cardiovascular Research Foundation’s Late-Spring Newsletter. With the changing of the seasons, CRF has also experienced change.

The Third Pulse of the City, a gala event in support of the Cardiovascular Research Foundation’s medical research and educational programs, will honor Dr Martin B. Leon, MD for his pioneering work in interventional cardiology. His commitment to improving survival and quality of life for countless individuals with heart disease will be recognized on Thursday, October 22, 2009 at The Waldorf=Astoria in New York, NY.

Respected health care executive takes the helm at pioneering foundation in interventional cardiology

New York, NY - April 20, 2009 - The Cardiovascular Research Foundation (CRF) today announced the appointment of William A. Himmelsbach, FACHE, as the foundation's new President and Chief Executive Officer. A well-respected and recognized expert in the health care field, Himmelsbach brings more than thirty years of leadership and management expertise to the organization. He succeeds Marvin L. Woodall, who is retiring. Mr. Himmelsbach was also appointed to CRF's Board of Directors.